Research Highlights Important Indicators of Early-stage Ovarian Cancer

	Tweet

New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment. The findings show that the difference between life and death can many times be explained by the different biological properties of the tumors. Understanding ovarian cancer biomarkers, such as clear cell tumors, and the exploration of specific tumor-targeted therapy, such as DNA profiling, will improve early stage diagnosis.

“Our findings show that continued research into identifying early-stage indicators for ovarian cancer will have a dramatic impact on long-term patient survival. Current practices, such as lymph node sampling, present only the first step towards an eventual cure,” says Ingiridur Skírnisdottir, lead author of the study.

Currently, less than 30 percent of women with ovarian cancer are diagnosed in the early stages of the disease, when it is confined to the ovaries (stage I) or when the spread has been limited to the pelvis (stage II). Although the long-term prognosis is better for patients with early-stage disease (10-year survival rates range from 50-70 percent) than for patients with advanced disease (where the 10-year survival rate is only 15-25 percent), up to 50 percent of women with early-stage ovarian cancer will eventually relapse and succumb to ovarian cancer.

This study is published in the November/December issue of International Journal of Gynecological Cancer. Media wishing to receive a PDF of this article may contact .

Ingiridur Skírnisdottir M.D., Ph.D is a gynecological surgeon in the Department of Women’s and Children’s Health, Obstetrics and Gynecology at Akademiska University Hospital in Uppsala, Sweden . Dr. Skírnisdottir can be reached at for questions at .

International Journal of Gynecological Cancer presents papers from throughout the global community of researchers covering many topics including basic science, epidemiology, diagnostic techniques, surgery, radiotherapy, chemotherapy, pathology and experimental studies. The Journal allows you to call on a roster of international experts for the latest research, advice, and knowledge in order to provide the best treatment for your patients. For more information, please visit www. blackwellpublishing.com/ijg.

RELATED STORIES:
Women often opt to surgically remove their breasts, ovaries to reduce cancer risk   Study Explains High Platelets in Ovarian Cancer Patients; Survival Reduced   More study needed on vitamin D-ovarian cancer link   Ovarian Cancer Responds to Aspirin Derivative with Chemotherapy   Ovarian Cancer: the Not-so-silent Killer   Hormone therapy linked to ovarian cancer risk   Electronic nose detects cancer   Nanotech gene therapy kills ovarian cancer in mice   Ovarian Cancer Treatment Found to Significantly Improve Survival   Ginger Causes Ovarian Cancer Cells to Die   Ovarian cancer subtypes are different diseases: Implications for biomarker studies   Tiny genetic variation can predict ovarian cancer outcome   Low-dose Pill reduces ovarian cancer risk   Protein compels ovarian cancer cells to cannibalize themselves   New Treatment Implications for Ovarian Cancer Unveiled   New treatment to overpower drug resistance in ovarian cancer   High dairy diet may up ovarian cancer risk   Extracellular protein sensitizes ovarian cancer cells to chemotherapy   Excess weight worsens ovarian cancer prognosis   UBC discovery may lead to ‘smart’ therapies for breast, ovarian cancer   Abdominal chemotherapy boosts survival in ovarian cancer patients   Ovarian cancer drug trial reveals promising new treatment

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]